In vivo binding of this ligand in PSP brains, however, showed no association with disease severity, which presumably is due to its unfavorable binding affinity (Kuntner et al., 2009) and its lack of specificity for tau aggregates (Tolboom et al., 2010). This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.